share_log

Aethlon Medical | 8-K: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical | 8-K: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical | 8-K：Aethlon Medical公布截至2024年9月30日的第二财季财务业绩，并提供公司最新情况
美股SEC公告 ·  2024/11/14 05:21

Moomoo AI 已提取核心信息

Aethlon Medical has achieved a significant milestone by enrolling its first two patients at Royal Adelaide Hospital in Australia for its Hemopurifier cancer trial. The company now has two Australian sites open for enrollment, with a third pending ethics approval. Additionally, they received ethics committee approval from Medanta Medicity Hospital in India for a similar trial.For Q2 FY2024 ended September 30, the company reported cash holdings of $6.9 million. Operating expenses decreased 9% to $2.9 million from $3.2 million YoY, primarily due to reduced professional fees of $600,000, partially offset by increased payroll expenses of $200,000 and general administrative costs of $100,000. Net loss improved to $2.8 million from $3.0 million in the prior year period.The company's Hemopurifier device, designed to combat cancer and viral infections, is undergoing safety and feasibility trials for patients with solid tumors who have failed anti-PD-1 antibody treatment. The study will examine the impact of 1-3 Hemopurifier treatments on extracellular vesicle concentrations and immune response to tumor cells.
Aethlon Medical has achieved a significant milestone by enrolling its first two patients at Royal Adelaide Hospital in Australia for its Hemopurifier cancer trial. The company now has two Australian sites open for enrollment, with a third pending ethics approval. Additionally, they received ethics committee approval from Medanta Medicity Hospital in India for a similar trial.For Q2 FY2024 ended September 30, the company reported cash holdings of $6.9 million. Operating expenses decreased 9% to $2.9 million from $3.2 million YoY, primarily due to reduced professional fees of $600,000, partially offset by increased payroll expenses of $200,000 and general administrative costs of $100,000. Net loss improved to $2.8 million from $3.0 million in the prior year period.The company's Hemopurifier device, designed to combat cancer and viral infections, is undergoing safety and feasibility trials for patients with solid tumors who have failed anti-PD-1 antibody treatment. The study will examine the impact of 1-3 Hemopurifier treatments on extracellular vesicle concentrations and immune response to tumor cells.
Aethlon Medical在澳洲皇家阿德莱德医院招募了首两名患者，已在其Hemopurifier癌症试验中取得了重要里程碑。目前该公司在澳洲已开放两个招募地点，第三个正在等待伦理批准。此外，他们还在印度Medanta Medicity医院获得了类似试验的伦理委员会批准。截至2024财年第二季度（9月30日），该公司报告现金持有量为690万。营业费用同比下降9%，从320万降至290万，主要由于减少了60万美元的专业费用，部分被20万美元的薪资费用和10万美元的一般行政费用所抵消。净亏损从去年同期的300万改善至280万。该公司的Hemopurifier设备旨在对抗癌症和病毒感染，目前正在对已接受抗PD-1抗体治疗失败的实体肿瘤患者进行安全性和可行性试验。该研究将考察1-3次Hemopurifier治疗对细胞外囊泡浓度和肿瘤细胞免疫反应的影响。
Aethlon Medical在澳洲皇家阿德莱德医院招募了首两名患者，已在其Hemopurifier癌症试验中取得了重要里程碑。目前该公司在澳洲已开放两个招募地点，第三个正在等待伦理批准。此外，他们还在印度Medanta Medicity医院获得了类似试验的伦理委员会批准。截至2024财年第二季度（9月30日），该公司报告现金持有量为690万。营业费用同比下降9%，从320万降至290万，主要由于减少了60万美元的专业费用，部分被20万美元的薪资费用和10万美元的一般行政费用所抵消。净亏损从去年同期的300万改善至280万。该公司的Hemopurifier设备旨在对抗癌症和病毒感染，目前正在对已接受抗PD-1抗体治疗失败的实体肿瘤患者进行安全性和可行性试验。该研究将考察1-3次Hemopurifier治疗对细胞外囊泡浓度和肿瘤细胞免疫反应的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    沃氪医疗
    WOK
    -- 0.566
    飞天兆业
    PTHL
    -- 3.740
    electroCore
    ECOR
    -- 6.8125
    VolitionRX
    VNRX
    -- 0.580
    Beta Bionics
    BBNX
    -- 12.240
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点